Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
SANTA CLARA, Calif., April 19, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has launched an e-commerce platform to support the commercialization of its Life Science products.
The launch follows the recent expansion of CrownBio’s Life Science division and answers the need to accommodate an increasing demand for the Company’s products.
CrownBio’s clients will now be able to purchase hundreds of products online across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immune checkpoint antibodies, and tumor tissue microarrays.
This digital tool facilitates and accelerates clients’ ordering, enabling them to create online accounts to track the history of their previous orders, save and share quotations for pending approval, and conveniently process transactions.
“We have created a digital user-friendly experience. Our platform has been updated to meet client expectations and provide an improved opportunity to purchase and deliver products online at CrownBio,” commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
“We remain impressed by the incredible growth and development of every division at CrownBio,” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. “In the Life Science sector, I am pleased we could successfully pivot CrownBio digital engagement efforts with the development of the e-commerce platform, which will ensure a client friendly, efficient experience to purchasing our products.”
CrownBio’s online shop can be accessed from the company website at this link https://www.crownbio.com/shop.
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
